<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799472</url>
  </required_header>
  <id_info>
    <org_study_id>205180</org_study_id>
    <nct_id>NCT02799472</nct_id>
  </id_info>
  <brief_title>Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore the activity of granulocyte-macrophage colony stimulating
      factor (GM-CSF) signaling pathway in subjects with rheumatoid arthritis (RA), the potential
      impact of inhibition of this axis by GSK3196165, and to evaluate whether there are any
      differences in the GM-CSF axis between subjects with early RA compared with those with more
      established disease. This study also aims to establish the potential impact of GSK3196165 on
      inflammatory structural joint damage in the hand/wrist using magnetic resonance imaging
      (MRI). This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled
      parallel group study. Approximately 40 subjects with active RA despite treatment with
      disease-modifying antirheumatic drugs (DMARDs) (including conventional or biologic) will be
      randomized into the study, following a screening period of up to 6 weeks. The total treatment
      period is up to 10 weeks, with a 12-week follow-up period after the last dose (Week 22).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week follow-up (FU) (Week 22)</time_frame>
    <description>Blood samples were collected for markers which may influence rheumatoid arthritis. Target engagement biomarkers included soluble GM-CSF complexed to GSK3196165. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for GM-CSF - Complex log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Analysis was performed on Intent-to-Treat (ITT) Population which consisted of all participants who were randomized to treatment and who received at least one dose of study treatment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Predictive Biomarkers: 14-3-3 ETA Protein, S100 Calcium Binding Protein (CBP) A8 and A9</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of 14-3-3 ETA Protein, S100 CBP A8 and A9. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for 14-3-3 ETA Protein (mg/L) and S100 CBP A8 and A9 log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Predictive Biomarkers: Amyloid A</measure>
    <time_frame>Baseline and Week 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Amyloid A. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Amyloid A log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data has been presented for only those time points at which the samples were collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Predictive Biomarkers: Amyloid A, Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand 13, Interleukin 6, Macrophage-Derived Chemokine</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Chemokine (C-C Motif) Ligand 17 (CL17), Chemokine (C-X-C Motif) Ligand 13 (CL13), Interleukin 6, Macrophage-Derived Chemokine (MDC). Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for CL17, CL13, Interleukin 6, MDC log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data has been presented for only those time points at which the samples were collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Predictive Biomarkers: Chitinase 3 Like 1, Matrix Metalloproteinase 3 (MMP-3)</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Chitinase 3 Like 1 and MMP-3. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Chitinase 3 Like 1 and MMP-3 log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cartilage Biomarkers</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers that may be predictive of rheumatoid arthritis disease activity. Cartilage biomarkers included analysis of ARGS Neo-Epitope, Citrullinated MMP-Degraded Vimentin (CMDV), MMP-Degraded C Reactive Protein (CRP), MMP-Degraded Type I Collagen (MD1C), MMP-Degraded Type II Collagen (MD2C), MMP-Degraded Type III Collagen (MD3C). Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for ARGS Neo-Epitope, Citrullinated MMP-Degraded Vimentin, MMP-Degraded CRP, MMP-Degraded Type I Collagen, MMP-Degraded Type II Collagen and MMP-Degraded Type III Collagen log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: Helper/Suppressor Cells</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of Helper/Suppressor. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Helper/Suppressor log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: 6 Colour TB Natural Killer (NK) Panel- CD16+CD56+, CD19, CD3, CD3+CD4+</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of cluster of differentiation (CD)16+CD56+, CD19, CD3, CD3+CD4+. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Repeated measures analysis adjusted for CD16+CD56+, CD19, CD3, CD3+CD4+, CD3+CD8+ and T Cell B Cell NKL log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: 6 Colour TBNK Panel- CD3+CD8+ and T Cell B Cell Natural Killer Lymphocytes (NKL)</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+CD8+ and T Cell B Cell NKL. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD3+CD8+ and T Cell B Cell NKL log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: T Regulatory (Reg) Cell Foxp3- CD3+ CD4+, CD3+ CD8+ and CD3+</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+ CD4+, CD3+ CD8+ and CD3+. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for CD3+ CD4+, CD3+ CD8+ and CD3+ Number of Cells (10^6/L) log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: T Reg Cell Foxp3: CD3+CD4+CD25+CD127-, CD3+CD4+foxP3+CD25+CD127-</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+CD4+CD25+CD127- and CD3+CD4+foxP3+CD25+CD127-. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD3+CD4+CD25+CD127- and CD3+CD4+foxP3+CD25+CD127-Number of Cells (10^6 cells/L) log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in T Helper Cell Panel Events</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. T Helper Cell Panel included analysis of CD45+3+8-4+CCR6+CXCR3+38+DR+, CD45+3+8-4+CCR6+CXCR3-38+DR+, CD45+3+8-4+CCR6-CXCR3+38+DR+, CD45+3+8-4+CCR6-CXCR3-38+DR+, CD45+CD3+CD8-CD4+, CD45+CD3+CD8-CD4+CCR6+CXCR3+, CD45+CD3+CD8-CD4+CCR6+CXCR3-, CD45+CD3+CD8-CD4+CCR6-CXCR3+ and CD45+CD3+CD8-CD4+CCR6-CXCR3-. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for T Helper Cell Panel Events (EVENTS) Baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16-, CD14lo+CD16br+</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16- and CD14lo+CD16br+. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16- and CD14lo+CD16br+ (10^3/Liter) baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-CD16+CD66b+</measure>
    <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD14-CD16+CD66b+ cell. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD14-CD16+CD66b+ (10^6/Liter) baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Biomarkers: Complement Component 3 (C3), Complement Component 4 (C4)</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Complement biomarkers included analysis of Complement C3 and Complement C4. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Complement Biomarkers: Complement Component 4a (C4a), Complement Component 5a (C5a), Complement Split Factor SC5b-9, Soluble Cluster of Differentiation 163 (sCD163)</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Complement biomarkers included analysis of Complement C4a, Complement C5a, Complement Split Factor SC5b-9 and Soluble CD163. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mechanistic Biomarkers</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Mechanistic biomarkers included analysis of Interleukin 1 Beta, Interleukin 10, Interleukin 15, Interleukin 17 Alpha, Interleukin 17F, Interleukin 8 and Tumor Necrosis Factor. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. NA indicates that data is not available since 100% of the data was below limit of quantification at all time points. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Safety Biomarkers: 3B-Cholestenoic Acid, Surfactant Protein D</measure>
    <time_frame>Baseline and Week 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Safety biomarkers included analysis of 3B-Cholestenoic Acid and Surfactant Protein D. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Safety Biomarkers: KL-6 Antigen</measure>
    <time_frame>Baseline and Week 12, 12-Week FU (Week 22)</time_frame>
    <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Safety biomarker included analysis of KL-6 Antigen. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Up to 12-Week FU (Week 22)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. An AESI include serious infections, opportunistic infections, neutropenia, respiratory events, pulmonary alveolar proteinosis, hypersensitivity reactions, injection site reactions, persistent cough or dyspnea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Tested Positive for Anti-GSK3196165 Binding Antibody Detection at Any Time Post-Baseline</measure>
    <time_frame>Up to 12-Week FU (Week 22)</time_frame>
    <description>Immunogenicity samples for determination of anti-drug-antibody (ADA) were collected. The presence of treatment emergent ADA was determined using a GSK3196165 bridging style ADA assay with a bio-analytically determined cut point determined during assay validation. Samples taken after dosing with GSK3196165 that had a value at or above the cut-point was considered potentially treatment-emergent ADA-positive. The immunogenicity population consisted of all participants in the ITT population, who had at least one valid immunogenicity assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Synovitis as Assessed by Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) in the Most Affected Hand/Wrist</measure>
    <time_frame>Baseline and Weeks 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>For synovitis a total of 8 joints were evaluated. Individual joint scores range from 0-3, where 0= normal, 1=mild, 2=moderate and 3=severe. The final synovitis score is the sum of the individual joint scores. Total score range from 0 (best) to 24 (worst). If an individual location is scored either 'Not Visible' or 'Surgically Modified' then the score for that location was set to missing. Missing joint scores was imputed as the mean of the non-missing joint scores. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Repeated measures analysis adjusted for synovitis score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Data has been presented for Median and 95% credible interval. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Osteitis as Assessed by OMERACT RAMRI Scoring System in the Most Affected Hand/Wrist</measure>
    <time_frame>Baseline and Weeks 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>For bone edema/osteitis a total of 25 locations was evaluated. Individual location scores ranged from 0-3, where, 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100% of bone edematous. Final bone edema/osteitis score is sum of individual location scores. Total score ranged from 0 (best) to 75 (worst). Baseline was defined at Day 1. Change from Baseline was calculated by subtracting post-dose value from Baseline value. If an individual location was scored either 'Not Visible' or 'Surgically Modified' or 'Not Assessable' then the score for that location was set to be missing. Missing joint scores was imputed as mean of non-missing location scores. Repeated measures analysis adjusted for Bone Edema/Osteitis Score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erosion as Assessed by OMERACT RAMRI Scoring System in the Most Affected Hand/Wrist</measure>
    <time_frame>Baseline and Weeks 4, 12, 12-Week FU (Week 22)</time_frame>
    <description>For bone erosion a total of 25 locations were evaluated. Individual location scores range from 0-10, where, 0: no erosion; 1: 1-10% of bone eroded and 10: 91-100% of bone eroded. The final bone erosion score is the sum of the individual location scores. The total score ranged from 0 (best) to 250 (worst). If an individual location was scored either 'Not Visible' or 'Surgically Modified' or 'Not Assessable' then the score for that location was set to be missing. Missing joint scores was imputed as the mean of the non-missing location scores. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for Bone Erosion Score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Synovitis as Assessed by Rheumatoid Arthritis MRI Quantitative (RAMRIQ) Assessment in the Most Affected Hand/Wrist</measure>
    <time_frame>Baseline and Weeks 4, 12 and 12-Week FU (Week 22)</time_frame>
    <description>RAMRIQ is an automated volume quantification assessment. RAMRIQ assessed same pathologies and joints (except metacarpophalangeal joint [MCP1]) as RAMRIS allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using active appearance modelling (AAMs). Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D regions of interest (ROI) for synovial enhancement across all time points. Synovial volume was calculated as voxels that enhance within each ROI. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Repeated measures analysis adjusted for Synovitis baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Osteitis as Assessed by RAMRIQ Assessment in the Most Affected Hand/Wrist</measure>
    <time_frame>Baseline and Weeks 4, 12 and 12-Week FU (Week 22)</time_frame>
    <description>RAMRIQ is an automated volume quantification assessment for edema volume. RAMRIQ assessed the same pathologies and joints (except MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs. Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D ROI for synovial enhancement across all time points. Edema volume was defined as non-erosion contrast-enhancing voxels inside the bone. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erosion as Assessed by RAMRIQ Assessment in the Most Affected Hand/Wrist</measure>
    <time_frame>Baseline and Weeks 4, 12 and 12-Week FU (Week 22)</time_frame>
    <description>RAMRIQ is an automated volume quantification assessment for erosion volume. RAMRIQ assessed the same pathologies and joints (except MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs. Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D ROI for synovial enhancement across all time points. Erosion volume was identified inside the bone surfaces using voxel-based classification. The volume of BME and erosions was normalised to total bone volume for statistical analysis. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>GSK3196165 + MTX arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (&gt;=5 mg/week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + MTX arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (&gt;=5 mg/week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3196165</intervention_name>
    <description>GSK3196165 is supplied as liquid and will be administered as SC injection.</description>
    <arm_group_label>GSK3196165 + MTX arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.</description>
    <arm_group_label>Placebo + MTX arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>Capsule, tablet or liquid administered orally or as SC injection.</description>
    <arm_group_label>GSK3196165 + MTX arm</arm_group_label>
    <arm_group_label>Placebo + MTX arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic (or folinic) acid</intervention_name>
    <description>Capsule, tablet or liquid and will be administered orally.</description>
    <arm_group_label>GSK3196165 + MTX arm</arm_group_label>
    <arm_group_label>Placebo + MTX arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years at the time of signing informed consent.

          -  Meets American College of Rheumatology (ACR)/European League Against Rheumatism
             (EULAR) 2010 RA Classification Criteria AND subject not diagnosed before age of 16
             years.

          -  Functional class I, II or III defined by the 1992 ACR Classification of Functional
             Status in RA.

          -  Active disease as defined by:

               -  Swollen joint count of &gt;=4 (66-joint count) and tender joint count of &gt;=4
                  (68-joint count) at screening and Day 1.

        AND • Disease activity score for 28 different joints with C-reactive protein (CRP) value
        (DAS28[CRP]) &gt;=3.2 at screening.

        AND

        • CRP &gt;=3.0 milligrams (mg)/liter (L).

          -  Signs of inflammation such as synovitis in the MRI scan of the most-affected hand.

          -  Must be currently taking MTX (15-25 mg weekly) (oral/injected) for at least 12 weeks
             before screening, with no change in route of administration, with a stable and
             tolerated dose for &gt;=4 weeks prior to Day 1. A stable dose of MTX &gt;=7.5 mg/week is
             acceptable, if the MTX dose has been reduced for reasons of documented intolerance to
             MTX, example (e.g.) hepatic or hematologic toxicity, or per local requirement.

          -  Body weight &gt;=45 kilograms (kg).

          -  Male or female subjects are eligible to participate so long as they meet and agree to
             abide by the contraceptive criteria.

          -  Capable of giving signed informed consent as described in protocol which includes
             compliance with the requirements and restrictions listed in the consent form and in
             the protocol.

          -  Willing to continue or initiate treatment with oral folic acid (at least 5 mg/week) or
             equivalent and be treated during the entire study (mandatory co-medication for MTX
             treatment).

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt;=60% predicted; forced
             expiratory volume in 1 second (FEV1) &gt;=70% predicted.

          -  No evidence of active or latent infection with Mycobacterium tuberculosis (TB).

        Exclusion Criteria:

          -  Pregnant or lactating, or women planning to become pregnant or initiating
             breastfeeding.

          -  History of other inflammatory rheumatologic or autoimmune disorders, other than
             Sjögren's syndrome secondary to RA.

          -  History of any respiratory disease which (in the opinion of the investigator) would
             compromise subject safety or the ability of the subject to complete the study (e.g.
             significant interstitial lung disease, such as pulmonary fibrosis, chronic obstructive
             pulmonary disease (COPD), moderate-severe asthma, bronchiectasis, previous pulmonary
             alveolar proteinosis [PAP]).

          -  Clinically-significant (in the opinion of the investigator) persistent cough or
             clinically significant or unstable dyspnea that is unexplained.

          -  Significant unstable or uncontrolled acute or chronic disease which, in the opinion of
             the investigator, could confound the results of the study or put the subject at undue
             risk.

          -  A history of malignancy.

          -  Contraindication to MRI scanning.

          -  Current/previous Hepatitis B virus (HBV), Hepatitis C virus (HCV) or human
             immunodeficiency virus (HIV) 1 or 2 infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erfurt</city>
        <state>Thueringen</state>
        <zip>99096</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puettlingen</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nowa Sol</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-128</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <results_first_submitted>October 16, 2018</results_first_submitted>
  <results_first_submitted_qc>October 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2018</results_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3196165</keyword>
  <keyword>magnetic resonance imaging (MRI)</keyword>
  <keyword>disease-modifying antirheumatic drugs (DMARDs)</keyword>
  <keyword>granulocyte-macrophage colony stimulating factor (GM-CSF)</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02799472/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02799472/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 39 participants with active early/established Rheumatoid arthritis were randomized across 9 centers in 3 countries from 15 June 2016 to 30 October 2017.</recruitment_details>
      <pre_assignment_details>Out of the 88 participants screened for this study, 49 participants were screen failures and 39 participants were randomized and received treatment in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Eligible participants received matching placebo subcutaneously (SC) into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received methotrexate (MTX) 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
        </group>
        <group group_id="P2">
          <title>GSK3196165 180 mg</title>
          <description>Eligible participants received GSK3196165 180 milligrams (mg) SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
        </group>
        <group group_id="B2">
          <title>GSK3196165 180 mg</title>
          <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="11.57"/>
                    <measurement group_id="B2" value="59.1" spread="9.47"/>
                    <measurement group_id="B3" value="56.6" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165</title>
        <description>Blood samples were collected for markers which may influence rheumatoid arthritis. Target engagement biomarkers included soluble GM-CSF complexed to GSK3196165. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for GM-CSF - Complex log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Analysis was performed on Intent-to-Treat (ITT) Population which consisted of all participants who were randomized to treatment and who received at least one dose of study treatment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week follow-up (FU) (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165</title>
          <description>Blood samples were collected for markers which may influence rheumatoid arthritis. Target engagement biomarkers included soluble GM-CSF complexed to GSK3196165. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for GM-CSF - Complex log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Analysis was performed on Intent-to-Treat (ITT) Population which consisted of all participants who were randomized to treatment and who received at least one dose of study treatment. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of GM-CSF complex</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GM-CSF - Complex, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" spread="35.98"/>
                    <measurement group_id="O2" value="13.799" spread="20.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF - Complex, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" spread="31.23"/>
                    <measurement group_id="O2" value="31.056" spread="17.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF - Complex, Week 4, n=8, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.959" spread="34.51"/>
                    <measurement group_id="O2" value="53.496" spread="18.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF - Complex, Week 6, n=7, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.964" spread="40.96"/>
                    <measurement group_id="O2" value="46.620" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF - Complex, Week 8, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.964" spread="41.80"/>
                    <measurement group_id="O2" value="33.404" spread="22.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF - Complex, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="44.95"/>
                    <measurement group_id="O2" value="22.556" spread="24.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF - Complex, 12-Week FU, n=8, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.954" spread="20.80"/>
                    <measurement group_id="O2" value="1.176" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>14.201</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.251</ci_lower_limit>
            <ci_upper_limit>32.262</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>32.360</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.828</ci_lower_limit>
            <ci_upper_limit>66.156</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>55.772</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.646</ci_lower_limit>
            <ci_upper_limit>121.287</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>48.336</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.341</ci_lower_limit>
            <ci_upper_limit>120.798</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>34.635</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.690</ci_lower_limit>
            <ci_upper_limit>87.629</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>23.249</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.579</ci_lower_limit>
            <ci_upper_limit>63.005</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GM-CSF - Complex, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.742</ci_lower_limit>
            <ci_upper_limit>2.048</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Predictive Biomarkers: 14-3-3 ETA Protein, S100 Calcium Binding Protein (CBP) A8 and A9</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of 14-3-3 ETA Protein, S100 CBP A8 and A9. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for 14-3-3 ETA Protein (mg/L) and S100 CBP A8 and A9 log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Predictive Biomarkers: 14-3-3 ETA Protein, S100 Calcium Binding Protein (CBP) A8 and A9</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of 14-3-3 ETA Protein, S100 CBP A8 and A9. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for 14-3-3 ETA Protein (mg/L) and S100 CBP A8 and A9 log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of predictive biomarker</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>14-3-3 ETA Protein, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.046" spread="3.88"/>
                    <measurement group_id="O2" value="0.986" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-3-3 ETA Protein, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.959" spread="12.14"/>
                    <measurement group_id="O2" value="0.986" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-3-3 ETA Protein, Week 4, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.128" spread="16.59"/>
                    <measurement group_id="O2" value="0.838" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-3-3 ETA Protein, Week 6, n=7, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.093" spread="15.55"/>
                    <measurement group_id="O2" value="0.833" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-3-3 ETA Protein, Week 8, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.950" spread="15.19"/>
                    <measurement group_id="O2" value="0.842" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-3-3 ETA Protein, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.131" spread="20.90"/>
                    <measurement group_id="O2" value="0.897" spread="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14-3-3 ETA Protein, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.040" spread="24.06"/>
                    <measurement group_id="O2" value="0.893" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.940" spread="15.20"/>
                    <measurement group_id="O2" value="0.939" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="15.28"/>
                    <measurement group_id="O2" value="0.823" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.874" spread="19.20"/>
                    <measurement group_id="O2" value="0.889" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.828" spread="21.92"/>
                    <measurement group_id="O2" value="0.812" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.804" spread="21.04"/>
                    <measurement group_id="O2" value="0.857" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.694" spread="21.61"/>
                    <measurement group_id="O2" value="0.879" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100 CBP A8 and A9, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.582" spread="20.60"/>
                    <measurement group_id="O2" value="1.018" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.193</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.943</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.861</ci_lower_limit>
            <ci_upper_limit>1.032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.842</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.776</ci_lower_limit>
            <ci_upper_limit>1.362</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.743</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.505</ci_lower_limit>
            <ci_upper_limit>1.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.137</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.762</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.531</ci_lower_limit>
            <ci_upper_limit>1.095</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.886</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.623</ci_lower_limit>
            <ci_upper_limit>1.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.338</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.793</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.488</ci_lower_limit>
            <ci_upper_limit>1.290</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>14-3-3 ETA Protein, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.582</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.859</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.491</ci_lower_limit>
            <ci_upper_limit>1.502</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.996</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.999</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.699</ci_lower_limit>
            <ci_upper_limit>1.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.745</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.944</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.662</ci_lower_limit>
            <ci_upper_limit>1.346</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.939</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.649</ci_lower_limit>
            <ci_upper_limit>1.593</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.937</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.981</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.595</ci_lower_limit>
            <ci_upper_limit>1.617</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.787</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.659</ci_lower_limit>
            <ci_upper_limit>1.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.267</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.769</ci_lower_limit>
            <ci_upper_limit>2.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>S100 CBP A8 and A9, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.748</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.076</ci_lower_limit>
            <ci_upper_limit>2.838</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Predictive Biomarkers: Amyloid A</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Amyloid A. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Amyloid A log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data has been presented for only those time points at which the samples were collected.</description>
        <time_frame>Baseline and Week 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Predictive Biomarkers: Amyloid A</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Amyloid A. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Amyloid A log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data has been presented for only those time points at which the samples were collected.</description>
          <population>ITT Population.</population>
          <units>Ratio of predictive biomarker</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amyloid A, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.845" spread="49.31"/>
                    <measurement group_id="O2" value="0.653" spread="25.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amyloid A, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.529" spread="35.12"/>
                    <measurement group_id="O2" value="0.623" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Amyloid A, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.632</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.774</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.261</ci_lower_limit>
            <ci_upper_limit>2.290</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Amyloid A, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.176</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.519</ci_lower_limit>
            <ci_upper_limit>2.663</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Predictive Biomarkers: Amyloid A, Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand 13, Interleukin 6, Macrophage-Derived Chemokine</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Chemokine (C-C Motif) Ligand 17 (CL17), Chemokine (C-X-C Motif) Ligand 13 (CL13), Interleukin 6, Macrophage-Derived Chemokine (MDC). Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for CL17, CL13, Interleukin 6, MDC log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data has been presented for only those time points at which the samples were collected.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Predictive Biomarkers: Amyloid A, Chemokine (C-C Motif) Ligand 17, Chemokine (C-X-C Motif) Ligand 13, Interleukin 6, Macrophage-Derived Chemokine</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Chemokine (C-C Motif) Ligand 17 (CL17), Chemokine (C-X-C Motif) Ligand 13 (CL13), Interleukin 6, Macrophage-Derived Chemokine (MDC). Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for CL17, CL13, Interleukin 6, MDC log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data has been presented for only those time points at which the samples were collected.</description>
          <population>ITT Population.</population>
          <units>Ratio of predictive biomarker</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CL17, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.117" spread="18.81"/>
                    <measurement group_id="O2" value="0.773" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL17, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.912" spread="24.37"/>
                    <measurement group_id="O2" value="0.651" spread="13.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL17, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.117" spread="21.91"/>
                    <measurement group_id="O2" value="0.679" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL17, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.032" spread="24.38"/>
                    <measurement group_id="O2" value="0.779" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL17, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.211" spread="20.63"/>
                    <measurement group_id="O2" value="0.675" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL17, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.711" spread="24.96"/>
                    <measurement group_id="O2" value="0.890" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL17, 12-Week FU, n=7, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.434" spread="23.26"/>
                    <measurement group_id="O2" value="1.357" spread="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.198" spread="15.63"/>
                    <measurement group_id="O2" value="0.915" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.090" spread="13.98"/>
                    <measurement group_id="O2" value="1.095" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.947" spread="15.58"/>
                    <measurement group_id="O2" value="1.170" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.839" spread="17.20"/>
                    <measurement group_id="O2" value="1.038" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.913" spread="23.70"/>
                    <measurement group_id="O2" value="1.021" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, Week 12, n=7,24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.924" spread="31.17"/>
                    <measurement group_id="O2" value="1.077" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CL13, 12-Week FU, n=7,21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.774" spread="27.82"/>
                    <measurement group_id="O2" value="1.224" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, Week 1, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.179" spread="27.92"/>
                    <measurement group_id="O2" value="1.064" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.153" spread="29.33"/>
                    <measurement group_id="O2" value="0.830" spread="16.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.986" spread="26.22"/>
                    <measurement group_id="O2" value="0.811" spread="15.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.136" spread="24.95"/>
                    <measurement group_id="O2" value="0.748" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.275" spread="23.65"/>
                    <measurement group_id="O2" value="0.872" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.770" spread="21.89"/>
                    <measurement group_id="O2" value="0.939" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.817" spread="33.13"/>
                    <measurement group_id="O2" value="1.308" spread="18.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.987" spread="5.02"/>
                    <measurement group_id="O2" value="0.914" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.925" spread="7.33"/>
                    <measurement group_id="O2" value="0.911" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.936" spread="8.13"/>
                    <measurement group_id="O2" value="0.895" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.984" spread="8.38"/>
                    <measurement group_id="O2" value="0.994" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.049" spread="9.36"/>
                    <measurement group_id="O2" value="0.899" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.245" spread="9.51"/>
                    <measurement group_id="O2" value="1.058" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC, 12-Week FU, n=7, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.303" spread="12.66"/>
                    <measurement group_id="O2" value="1.321" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL17, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.692</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.445</ci_lower_limit>
            <ci_upper_limit>1.074</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL17, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.713</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.407</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL17, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.608</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.365</ci_lower_limit>
            <ci_upper_limit>1.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL17, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.307</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.435</ci_lower_limit>
            <ci_upper_limit>1.309</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL17, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.557</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.894</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.520</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.294</ci_lower_limit>
            <ci_upper_limit>0.922</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL17, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.839</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.947</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.548</ci_lower_limit>
            <ci_upper_limit>1.636</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.764</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.530</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.976</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.726</ci_lower_limit>
            <ci_upper_limit>1.390</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.244</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.859</ci_lower_limit>
            <ci_upper_limit>1.778</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.278</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.836</ci_lower_limit>
            <ci_upper_limit>1.830</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.118</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.651</ci_lower_limit>
            <ci_upper_limit>1.920</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.661</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.573</ci_lower_limit>
            <ci_upper_limit>2.369</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CL13, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.581</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.832</ci_lower_limit>
            <ci_upper_limit>3.007</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.751</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.903</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.471</ci_lower_limit>
            <ci_upper_limit>1.729</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.330</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.720</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.367</ci_lower_limit>
            <ci_upper_limit>1.413</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.822</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.447</ci_lower_limit>
            <ci_upper_limit>1.512</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.659</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.372</ci_lower_limit>
            <ci_upper_limit>1.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.684</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.396</ci_lower_limit>
            <ci_upper_limit>1.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.432</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.221</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.734</ci_lower_limit>
            <ci_upper_limit>2.031</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.216</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.602</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>3.423</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.926</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.823</ci_lower_limit>
            <ci_upper_limit>1.042</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.851</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.984</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.829</ci_lower_limit>
            <ci_upper_limit>1.168</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.637</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.956</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.790</ci_lower_limit>
            <ci_upper_limit>1.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.857</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.690</ci_lower_limit>
            <ci_upper_limit>1.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.142</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.849</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.681</ci_lower_limit>
            <ci_upper_limit>1.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MDC, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.929</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.745</ci_lower_limit>
            <ci_upper_limit>1.378</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Predictive Biomarkers: Chitinase 3 Like 1, Matrix Metalloproteinase 3 (MMP-3)</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Chitinase 3 Like 1 and MMP-3. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Chitinase 3 Like 1 and MMP-3 log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Predictive Biomarkers: Chitinase 3 Like 1, Matrix Metalloproteinase 3 (MMP-3)</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Predictive biomarkers included analysis of Chitinase 3 Like 1 and MMP-3. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Chitinase 3 Like 1 and MMP-3 log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of predictive biomarker</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chitinase 3 Like 1, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.033" spread="13.97"/>
                    <measurement group_id="O2" value="0.917" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitinase 3 Like 1, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.013" spread="15.05"/>
                    <measurement group_id="O2" value="0.966" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitinase 3 Like 1, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.961" spread="17.14"/>
                    <measurement group_id="O2" value="1.088" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitinase 3 Like 1, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.897" spread="17.08"/>
                    <measurement group_id="O2" value="1.031" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitinase 3 Like 1, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.851" spread="18.24"/>
                    <measurement group_id="O2" value="0.947" spread="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitinase 3 Like 1, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.066" spread="21.53"/>
                    <measurement group_id="O2" value="1.071" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chitinase 3 Like 1, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.735" spread="16.87"/>
                    <measurement group_id="O2" value="1.019" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP 3, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.076" spread="6.72"/>
                    <measurement group_id="O2" value="0.984" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-3, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.067" spread="7.26"/>
                    <measurement group_id="O2" value="1.024" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-3, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.112" spread="8.30"/>
                    <measurement group_id="O2" value="1.016" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-3, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" spread="26.26"/>
                    <measurement group_id="O2" value="0.804" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-3, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.939" spread="15.43"/>
                    <measurement group_id="O2" value="1.088" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-3, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="13.57"/>
                    <measurement group_id="O2" value="0.951" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-3, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.803" spread="16.05"/>
                    <measurement group_id="O2" value="0.984" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.463</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.887</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.640</ci_lower_limit>
            <ci_upper_limit>1.231</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.782</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.953</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.672</ci_lower_limit>
            <ci_upper_limit>1.352</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.132</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.759</ci_lower_limit>
            <ci_upper_limit>1.690</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.473</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.779</ci_lower_limit>
            <ci_upper_limit>1.694</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.608</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.733</ci_lower_limit>
            <ci_upper_limit>1.687</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.985</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.613</ci_lower_limit>
            <ci_upper_limit>1.645</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chitinase 3 Like 1, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.386</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.934</ci_lower_limit>
            <ci_upper_limit>2.057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.259</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.915</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.781</ci_lower_limit>
            <ci_upper_limit>1.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.959</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.354</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.914</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.752</ci_lower_limit>
            <ci_upper_limit>1.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.448</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.800</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.443</ci_lower_limit>
            <ci_upper_limit>1.444</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.402</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.160</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.813</ci_lower_limit>
            <ci_upper_limit>1.653</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.745</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.951</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.695</ci_lower_limit>
            <ci_upper_limit>1.301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-3, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.279</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.226</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.837</ci_lower_limit>
            <ci_upper_limit>1.796</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cartilage Biomarkers</title>
        <description>Blood samples were collected and analyzed for markers that may be predictive of rheumatoid arthritis disease activity. Cartilage biomarkers included analysis of ARGS Neo-Epitope, Citrullinated MMP-Degraded Vimentin (CMDV), MMP-Degraded C Reactive Protein (CRP), MMP-Degraded Type I Collagen (MD1C), MMP-Degraded Type II Collagen (MD2C), MMP-Degraded Type III Collagen (MD3C). Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for ARGS Neo-Epitope, Citrullinated MMP-Degraded Vimentin, MMP-Degraded CRP, MMP-Degraded Type I Collagen, MMP-Degraded Type II Collagen and MMP-Degraded Type III Collagen log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Biomarkers</title>
          <description>Blood samples were collected and analyzed for markers that may be predictive of rheumatoid arthritis disease activity. Cartilage biomarkers included analysis of ARGS Neo-Epitope, Citrullinated MMP-Degraded Vimentin (CMDV), MMP-Degraded C Reactive Protein (CRP), MMP-Degraded Type I Collagen (MD1C), MMP-Degraded Type II Collagen (MD2C), MMP-Degraded Type III Collagen (MD3C). Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for ARGS Neo-Epitope, Citrullinated MMP-Degraded Vimentin, MMP-Degraded CRP, MMP-Degraded Type I Collagen, MMP-Degraded Type II Collagen and MMP-Degraded Type III Collagen log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of cartilage biomarker</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ARGS Neo-Epitope, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" spread="16.10"/>
                    <measurement group_id="O2" value="1.075" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARGS Neo-Epitope, Week 2, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.790" spread="17.38"/>
                    <measurement group_id="O2" value="1.249" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARGS Neo-Epitope, Week 4, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.904" spread="17.02"/>
                    <measurement group_id="O2" value="1.104" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARGS Neo-Epitope, Week 6, n=6, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.894" spread="14.28"/>
                    <measurement group_id="O2" value="1.164" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARGS Neo-Epitope, Week 8, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.854" spread="26.42"/>
                    <measurement group_id="O2" value="1.238" spread="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARGS Neo-Epitope, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.913" spread="13.97"/>
                    <measurement group_id="O2" value="1.156" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARGS Neo-Epitope, 12-Week FU, n=8, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.129" spread="17.44"/>
                    <measurement group_id="O2" value="1.124" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV, Week 1,n=9,27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" spread="24.12"/>
                    <measurement group_id="O2" value="0.876" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV,Week 2,n=8,26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.820" spread="28.46"/>
                    <measurement group_id="O2" value="0.714" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV, Week 4,n=9,27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.715" spread="27.30"/>
                    <measurement group_id="O2" value="0.801" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV, Week 6,n=7,27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.099" spread="30.47"/>
                    <measurement group_id="O2" value="0.726" spread="15.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV, Week 8,n=7,25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.929" spread="24.72"/>
                    <measurement group_id="O2" value="0.759" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV, Week12,n=7,24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.123" spread="29.34"/>
                    <measurement group_id="O2" value="0.917" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CMDV, 12-Week FU,n=7,21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.936" spread="28.05"/>
                    <measurement group_id="O2" value="0.769" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.971" spread="6.83"/>
                    <measurement group_id="O2" value="1.021" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="5.55"/>
                    <measurement group_id="O2" value="1.000" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.992" spread="6.01"/>
                    <measurement group_id="O2" value="1.004" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.122" spread="6.55"/>
                    <measurement group_id="O2" value="1.099" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.977" spread="7.37"/>
                    <measurement group_id="O2" value="1.087" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.006" spread="7.13"/>
                    <measurement group_id="O2" value="1.108" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP-Degraded CRP, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.075" spread="8.01"/>
                    <measurement group_id="O2" value="1.129" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.079" spread="9.60"/>
                    <measurement group_id="O2" value="0.858" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.028" spread="11.98"/>
                    <measurement group_id="O2" value="0.907" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.142" spread="14.57"/>
                    <measurement group_id="O2" value="0.896" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.392" spread="12.64"/>
                    <measurement group_id="O2" value="0.889" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.131" spread="13.05"/>
                    <measurement group_id="O2" value="0.904" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.148" spread="13.74"/>
                    <measurement group_id="O2" value="1.023" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD1C, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.095" spread="14.21"/>
                    <measurement group_id="O2" value="0.952" spread="8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.059" spread="11.83"/>
                    <measurement group_id="O2" value="1.038" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.046" spread="11.27"/>
                    <measurement group_id="O2" value="1.015" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.035" spread="10.18"/>
                    <measurement group_id="O2" value="1.003" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.158" spread="12.07"/>
                    <measurement group_id="O2" value="1.064" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.091" spread="11.42"/>
                    <measurement group_id="O2" value="1.023" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.174" spread="10.73"/>
                    <measurement group_id="O2" value="1.072" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD2C, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.338" spread="13.10"/>
                    <measurement group_id="O2" value="1.041" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.950" spread="6.44"/>
                    <measurement group_id="O2" value="0.959" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.920" spread="6.82"/>
                    <measurement group_id="O2" value="0.954" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.940" spread="8.06"/>
                    <measurement group_id="O2" value="0.886" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.013" spread="8.09"/>
                    <measurement group_id="O2" value="0.894" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.918" spread="9.04"/>
                    <measurement group_id="O2" value="0.881" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.929" spread="9.28"/>
                    <measurement group_id="O2" value="0.910" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MD3C, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.847" spread="9.75"/>
                    <measurement group_id="O2" value="0.910" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.098</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>1.606</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.581</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.046</ci_lower_limit>
            <ci_upper_limit>2.388</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.222</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.817</ci_lower_limit>
            <ci_upper_limit>1.827</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.302</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.936</ci_lower_limit>
            <ci_upper_limit>1.810</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.217</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.450</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.795</ci_lower_limit>
            <ci_upper_limit>2.645</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.266</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.916</ci_lower_limit>
            <ci_upper_limit>1.750</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ARGS Neo-Epitope, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.985</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.996</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.662</ci_lower_limit>
            <ci_upper_limit>1.499</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.681</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.892</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.511</ci_lower_limit>
            <ci_upper_limit>1.560</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.870</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.454</ci_lower_limit>
            <ci_upper_limit>1.669</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.717</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.120</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.597</ci_lower_limit>
            <ci_upper_limit>2.101</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.661</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.333</ci_lower_limit>
            <ci_upper_limit>1.310</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.817</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.464</ci_lower_limit>
            <ci_upper_limit>1.437</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.541</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.816</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.417</ci_lower_limit>
            <ci_upper_limit>1.597</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CMDV, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.544</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.822</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.422</ci_lower_limit>
            <ci_upper_limit>1.602</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.537</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.895</ci_lower_limit>
            <ci_upper_limit>1.233</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.635</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.906</ci_lower_limit>
            <ci_upper_limit>1.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.866</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.879</ci_lower_limit>
            <ci_upper_limit>1.165</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.780</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.979</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.842</ci_lower_limit>
            <ci_upper_limit>1.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.113</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.938</ci_lower_limit>
            <ci_upper_limit>1.320</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.242</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.934</ci_lower_limit>
            <ci_upper_limit>1.300</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMP-Degraded CRP, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.597</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.870</ci_lower_limit>
            <ci_upper_limit>1.267</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.795</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.634</ci_lower_limit>
            <ci_upper_limit>0.997</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.367</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.883</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.668</ci_lower_limit>
            <ci_upper_limit>1.165</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.784</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.558</ci_lower_limit>
            <ci_upper_limit>1.102</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.638</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.477</ci_lower_limit>
            <ci_upper_limit>0.855</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.799</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.591</ci_lower_limit>
            <ci_upper_limit>1.080</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.470</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.891</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.647</ci_lower_limit>
            <ci_upper_limit>1.228</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD1C, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.869</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.621</ci_lower_limit>
            <ci_upper_limit>1.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.887</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.981</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.742</ci_lower_limit>
            <ci_upper_limit>1.296</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.814</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.970</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.744</ci_lower_limit>
            <ci_upper_limit>1.263</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.794</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.969</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.762</ci_lower_limit>
            <ci_upper_limit>1.233</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.539</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.919</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.696</ci_lower_limit>
            <ci_upper_limit>1.213</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.937</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.719</ci_lower_limit>
            <ci_upper_limit>1.221</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.467</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.913</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.711</ci_lower_limit>
            <ci_upper_limit>1.173</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD2C, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.778</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.570</ci_lower_limit>
            <ci_upper_limit>1.061</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.897</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.868</ci_lower_limit>
            <ci_upper_limit>1.175</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, Week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.644</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.884</ci_lower_limit>
            <ci_upper_limit>1.218</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.943</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.780</ci_lower_limit>
            <ci_upper_limit>1.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, Week 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.882</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.733</ci_lower_limit>
            <ci_upper_limit>1.063</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, Week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.691</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.960</param_value>
            <ci_percent>10</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.779</ci_lower_limit>
            <ci_upper_limit>1.182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.843</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.979</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.790</ci_lower_limit>
            <ci_upper_limit>1.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MD3C, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.524</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.075</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.855</ci_lower_limit>
            <ci_upper_limit>1.351</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: Helper/Suppressor Cells</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of Helper/Suppressor. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Helper/Suppressor log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: Helper/Suppressor Cells</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of Helper/Suppressor. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for Helper/Suppressor log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of Helper/Suppressor cells</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Helper/Suppressor, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.024" spread="6.98"/>
                    <measurement group_id="O2" value="0.976" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helper/Suppressor, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.053" spread="7.18"/>
                    <measurement group_id="O2" value="0.998" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helper/Suppressor, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.040" spread="6.83"/>
                    <measurement group_id="O2" value="1.088" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helper/Suppressor, 12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.051" spread="8.99"/>
                    <measurement group_id="O2" value="1.065" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Helper/Suppressor, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.558</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.953</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Helper/Suppressor, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.515</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.947</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.801</ci_lower_limit>
            <ci_upper_limit>1.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Helper/Suppressor, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.565</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.895</ci_lower_limit>
            <ci_upper_limit>1.222</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Helper/Suppressor, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.897</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.822</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: 6 Colour TB Natural Killer (NK) Panel- CD16+CD56+, CD19, CD3, CD3+CD4+</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of cluster of differentiation (CD)16+CD56+, CD19, CD3, CD3+CD4+. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Repeated measures analysis adjusted for CD16+CD56+, CD19, CD3, CD3+CD4+, CD3+CD8+ and T Cell B Cell NKL log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: 6 Colour TB Natural Killer (NK) Panel- CD16+CD56+, CD19, CD3, CD3+CD4+</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of cluster of differentiation (CD)16+CD56+, CD19, CD3, CD3+CD4+. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Repeated measures analysis adjusted for CD16+CD56+, CD19, CD3, CD3+CD4+, CD3+CD8+ and T Cell B Cell NKL log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of biomarker</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD16+CD56+, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" spread="11.39"/>
                    <measurement group_id="O2" value="1.025" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+CD56+, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.163" spread="12.97"/>
                    <measurement group_id="O2" value="0.951" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+CD56+, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.193" spread="15.49"/>
                    <measurement group_id="O2" value="0.911" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD16+CD56+, 12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.298" spread="15.10"/>
                    <measurement group_id="O2" value="0.920" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.880" spread="11.05"/>
                    <measurement group_id="O2" value="0.984" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.090" spread="15.31"/>
                    <measurement group_id="O2" value="0.971" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.054" spread="12.26"/>
                    <measurement group_id="O2" value="1.003" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19, Week 22, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" spread="17.75"/>
                    <measurement group_id="O2" value="0.938" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.918" spread="8.73"/>
                    <measurement group_id="O2" value="0.994" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" spread="11.79"/>
                    <measurement group_id="O2" value="0.934" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.912" spread="9.01"/>
                    <measurement group_id="O2" value="0.992" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3, 12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" spread="9.17"/>
                    <measurement group_id="O2" value="0.989" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.926" spread="9.56"/>
                    <measurement group_id="O2" value="0.991" spread="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.028" spread="12.80"/>
                    <measurement group_id="O2" value="0.933" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" spread="9.69"/>
                    <measurement group_id="O2" value="1.013" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, 12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" spread="9.92"/>
                    <measurement group_id="O2" value="1.000" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD16+CD56+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.786</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.794</ci_lower_limit>
            <ci_upper_limit>1.354</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD16+CD56+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.603</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD16+CD56+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.763</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.536</ci_lower_limit>
            <ci_upper_limit>1.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD16+CD56+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.709</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.499</ci_lower_limit>
            <ci_upper_limit>1.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD19, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.383</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.119</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.863</ci_lower_limit>
            <ci_upper_limit>1.450</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD19, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.890</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.623</ci_lower_limit>
            <ci_upper_limit>1.271</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD19, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.952</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.718</ci_lower_limit>
            <ci_upper_limit>1.262</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD19, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.831</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.958</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.635</ci_lower_limit>
            <ci_upper_limit>1.443</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.437</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.882</ci_lower_limit>
            <ci_upper_limit>1.328</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.632</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.937</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.711</ci_lower_limit>
            <ci_upper_limit>1.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.413</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.885</ci_lower_limit>
            <ci_upper_limit>1.336</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.858</ci_lower_limit>
            <ci_upper_limit>1.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.547</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.855</ci_lower_limit>
            <ci_upper_limit>1.338</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.907</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>1.223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.573</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.064</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.853</ci_lower_limit>
            <ci_upper_limit>1.328</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.789</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.818</ci_lower_limit>
            <ci_upper_limit>1.300</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: 6 Colour TBNK Panel- CD3+CD8+ and T Cell B Cell Natural Killer Lymphocytes (NKL)</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+CD8+ and T Cell B Cell NKL. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD3+CD8+ and T Cell B Cell NKL log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: 6 Colour TBNK Panel- CD3+CD8+ and T Cell B Cell Natural Killer Lymphocytes (NKL)</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+CD8+ and T Cell B Cell NKL. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD3+CD8+ and T Cell B Cell NKL log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>10^9 cells/Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3+CD8+, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.041" spread="0.0390"/>
                    <measurement group_id="O2" value="-0.005" spread="0.0222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0580"/>
                    <measurement group_id="O2" value="-0.023" spread="0.0327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.0418"/>
                    <measurement group_id="O2" value="-0.037" spread="0.0215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, 12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.060" spread="0.0506"/>
                    <measurement group_id="O2" value="-0.027" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T Cell B Cell NKL, Week 1, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.123" spread="0.1557"/>
                    <measurement group_id="O2" value="-0.020" spread="0.0881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T Cell B Cell NKL, Week 4, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.108" spread="0.2174"/>
                    <measurement group_id="O2" value="-0.050" spread="0.1229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T Cell B Cell NKL, Week 12, n=6, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.093" spread="0.1792"/>
                    <measurement group_id="O2" value="-0.006" spread="0.0925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T Cell B Cell NKL, 12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.2168"/>
                    <measurement group_id="O2" value="-0.050" spread="0.1183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD8+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.428</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.056</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD8+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.159</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD8+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD8+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.569</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.084</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T Cell B Cell NKL, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.569</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.103</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.263</ci_lower_limit>
            <ci_upper_limit>0.469</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T Cell B Cell NKL, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.534</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.157</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.668</ci_lower_limit>
            <ci_upper_limit>0.354</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T Cell B Cell NKL, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.323</ci_lower_limit>
            <ci_upper_limit>0.498</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T Cell B Cell NKL, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.934</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.526</ci_lower_limit>
            <ci_upper_limit>0.484</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: T Regulatory (Reg) Cell Foxp3- CD3+ CD4+, CD3+ CD8+ and CD3+</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+ CD4+, CD3+ CD8+ and CD3+. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for CD3+ CD4+, CD3+ CD8+ and CD3+ Number of Cells (10^6/L) log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: T Regulatory (Reg) Cell Foxp3- CD3+ CD4+, CD3+ CD8+ and CD3+</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+ CD4+, CD3+ CD8+ and CD3+. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Analysis was performed using repeated measures analysis adjusted for CD3+ CD4+, CD3+ CD8+ and CD3+ Number of Cells (10^6/L) log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of T Reg cell</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3+ CD4+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" spread="10.21"/>
                    <measurement group_id="O2" value="1.007" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD4+, Week 4, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.038" spread="11.31"/>
                    <measurement group_id="O2" value="0.976" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD4+, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" spread="10.55"/>
                    <measurement group_id="O2" value="1.004" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD4+, 12-Week FU, n=5, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.926" spread="11.70"/>
                    <measurement group_id="O2" value="1.003" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD8+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.885" spread="9.97"/>
                    <measurement group_id="O2" value="0.983" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD8+, Week 4, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" spread="11.89"/>
                    <measurement group_id="O2" value="0.939" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD8+, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.878" spread="10.50"/>
                    <measurement group_id="O2" value="0.945" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+ CD8+, 12-Week FU, n=5, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.936" spread="10.99"/>
                    <measurement group_id="O2" value="0.965" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.901" spread="9.98"/>
                    <measurement group_id="O2" value="0.992" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, Week 4, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.034" spread="12.99"/>
                    <measurement group_id="O2" value="0.938" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.959" spread="9.62"/>
                    <measurement group_id="O2" value="0.993" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, 12-Week FU, n=5, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.944" spread="10.88"/>
                    <measurement group_id="O2" value="0.991" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD4+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.876</ci_lower_limit>
            <ci_upper_limit>1.412</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD4+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.641</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.941</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.721</ci_lower_limit>
            <ci_upper_limit>1.228</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD4+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.804</ci_lower_limit>
            <ci_upper_limit>1.303</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD4+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.558</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.082</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.821</ci_lower_limit>
            <ci_upper_limit>1.427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD8+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.363</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.880</ci_lower_limit>
            <ci_upper_limit>1.402</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD8+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.751</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.957</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.724</ci_lower_limit>
            <ci_upper_limit>1.265</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD8+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.537</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.076</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.846</ci_lower_limit>
            <ci_upper_limit>1.370</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+ CD8+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.797</ci_lower_limit>
            <ci_upper_limit>1.335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.405</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.101</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.872</ci_lower_limit>
            <ci_upper_limit>1.391</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.907</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.668</ci_lower_limit>
            <ci_upper_limit>1.232</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.748</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>1.291</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.704</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Ratio</param_type>
            <param_value>1.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.811</ci_lower_limit>
            <ci_upper_limit>1.356</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: T Reg Cell Foxp3: CD3+CD4+CD25+CD127-, CD3+CD4+foxP3+CD25+CD127-</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+CD4+CD25+CD127- and CD3+CD4+foxP3+CD25+CD127-. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD3+CD4+CD25+CD127- and CD3+CD4+foxP3+CD25+CD127-Number of Cells (10^6 cells/L) log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: T Reg Cell Foxp3: CD3+CD4+CD25+CD127-, CD3+CD4+foxP3+CD25+CD127-</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD3+CD4+CD25+CD127- and CD3+CD4+foxP3+CD25+CD127-. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD3+CD4+CD25+CD127- and CD3+CD4+foxP3+CD25+CD127-Number of Cells (10^6 cells/L) log(Baseline value), treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>10^6 cells/Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3+CD4+CD25+CD127-, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="8.35"/>
                    <measurement group_id="O2" value="2.9" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+CD25+CD127-, Week 4, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="8.34"/>
                    <measurement group_id="O2" value="-0.4" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+CD25+CD127-, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="9.87"/>
                    <measurement group_id="O2" value="-3.1" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+CD25+CD127-, 12-Week FU, n=5, 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" spread="9.92"/>
                    <measurement group_id="O2" value="-2.3" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+foxP3+CD25+CD127, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="6.39"/>
                    <measurement group_id="O2" value="2.8" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+foxP3+CD25+CD127, Week 4, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="7.05"/>
                    <measurement group_id="O2" value="2.0" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+foxP3+CD25+CD127, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.99"/>
                    <measurement group_id="O2" value="-4.4" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+foxP3+CD25+CD127,12-Week FU, n=5,17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="5.94"/>
                    <measurement group_id="O2" value="-4.6" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+CD25+CD127-, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.501</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.1</ci_lower_limit>
            <ci_upper_limit>26.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+CD25+CD127-, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.852</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.6</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+CD25+CD127-, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.572</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>29.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+CD25+CD127-, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.363</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.0</ci_lower_limit>
            <ci_upper_limit>34.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+foxP3+CD25+CD127-, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.788</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.0</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+foxP3+CD25+CD127-, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.786</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.8</ci_lower_limit>
            <ci_upper_limit>14.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+foxP3+CD25+CD127-, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.433</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.4</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD3+CD4+foxP3+CD25+CD127-, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.550</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in T Helper Cell Panel Events</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. T Helper Cell Panel included analysis of CD45+3+8-4+CCR6+CXCR3+38+DR+, CD45+3+8-4+CCR6+CXCR3-38+DR+, CD45+3+8-4+CCR6-CXCR3+38+DR+, CD45+3+8-4+CCR6-CXCR3-38+DR+, CD45+CD3+CD8-CD4+, CD45+CD3+CD8-CD4+CCR6+CXCR3+, CD45+CD3+CD8-CD4+CCR6+CXCR3-, CD45+CD3+CD8-CD4+CCR6-CXCR3+ and CD45+CD3+CD8-CD4+CCR6-CXCR3-. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for T Helper Cell Panel Events (EVENTS) Baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in T Helper Cell Panel Events</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. T Helper Cell Panel included analysis of CD45+3+8-4+CCR6+CXCR3+38+DR+, CD45+3+8-4+CCR6+CXCR3-38+DR+, CD45+3+8-4+CCR6-CXCR3+38+DR+, CD45+3+8-4+CCR6-CXCR3-38+DR+, CD45+CD3+CD8-CD4+, CD45+CD3+CD8-CD4+CCR6+CXCR3+, CD45+CD3+CD8-CD4+CCR6+CXCR3-, CD45+CD3+CD8-CD4+CCR6-CXCR3+ and CD45+CD3+CD8-CD4+CCR6-CXCR3-. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for T Helper Cell Panel Events (EVENTS) Baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Events</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3+38+DR+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.6" spread="13.50"/>
                    <measurement group_id="O2" value="-34.0" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3+38+DR+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="18.36"/>
                    <measurement group_id="O2" value="-6.1" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3+38+DR+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="37.80"/>
                    <measurement group_id="O2" value="-6.9" spread="17.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3+38+DR+,12-Week FU,n=5,18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="16.47"/>
                    <measurement group_id="O2" value="-18.7" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3-38+DR+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="6.80"/>
                    <measurement group_id="O2" value="-10.5" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3-38+DR+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="15.65"/>
                    <measurement group_id="O2" value="12.2" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3-38+DR+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="16.09"/>
                    <measurement group_id="O2" value="-3.0" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6+CXCR3-38+DR+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="12.29"/>
                    <measurement group_id="O2" value="3.3" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3+38+DR+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.2" spread="82.46"/>
                    <measurement group_id="O2" value="-129.2" spread="46.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3+38+DR+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-159.6" spread="60.51"/>
                    <measurement group_id="O2" value="-108.0" spread="35.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3+38+DR+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.2" spread="299.65"/>
                    <measurement group_id="O2" value="77.7" spread="146.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3+38+DR+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="66.09"/>
                    <measurement group_id="O2" value="-104.0" spread="34.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3-38+DR+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.9" spread="25.90"/>
                    <measurement group_id="O2" value="-70.5" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3-38+DR+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="30.69"/>
                    <measurement group_id="O2" value="-56.3" spread="17.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3-38+DR+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="198.13"/>
                    <measurement group_id="O2" value="43.0" spread="92.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+3+8-4+CCR6-CXCR3-38+DR+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="33.50"/>
                    <measurement group_id="O2" value="-59.9" spread="17.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3845.3" spread="2648.60"/>
                    <measurement group_id="O2" value="-163.0" spread="1444.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1622.8" spread="2973.60"/>
                    <measurement group_id="O2" value="1075.1" spread="1723.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vCD45+CD3+CD8-CD4+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2112.9" spread="4211.63"/>
                    <measurement group_id="O2" value="1006.9" spread="2026.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1799.0" spread="2589.05"/>
                    <measurement group_id="O2" value="-1832.0" spread="1366.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-514.6" spread="647.85"/>
                    <measurement group_id="O2" value="-1030.2" spread="345.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-116.6" spread="757.58"/>
                    <measurement group_id="O2" value="-316.5" spread="438.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-252.9" spread="827.53"/>
                    <measurement group_id="O2" value="-506.4" spread="389.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-688.1" spread="792.26"/>
                    <measurement group_id="O2" value="-463.0" spread="412.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3-, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-817.1" spread="393.10"/>
                    <measurement group_id="O2" value="-654.5" spread="212.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3-, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.7" spread="475.88"/>
                    <measurement group_id="O2" value="14.2" spread="277.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3-, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="541.14"/>
                    <measurement group_id="O2" value="-219.7" spread="253.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6+CXCR3-, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-311.6" spread="553.32"/>
                    <measurement group_id="O2" value="-509.2" spread="291.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3+, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371.8" spread="1026.17"/>
                    <measurement group_id="O2" value="1521.8" spread="547.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3+, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="1678.23"/>
                    <measurement group_id="O2" value="-292.5" spread="967.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3+, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2790.5" spread="2510.67"/>
                    <measurement group_id="O2" value="1443.1" spread="1209.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2295.9" spread="1787.02"/>
                    <measurement group_id="O2" value="607.0" spread="927.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3-, Week 1, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3231.4" spread="2162.58"/>
                    <measurement group_id="O2" value="45.4" spread="1187.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3-, Week 4, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2084.9" spread="2873.95"/>
                    <measurement group_id="O2" value="1637.6" spread="1665.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3-, Week 12, n=5, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1273.9" spread="2413.90"/>
                    <measurement group_id="O2" value="161.4" spread="1209.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45+CD3+CD8-CD4+CCR6-CXCR3-, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-106.6" spread="1690.64"/>
                    <measurement group_id="O2" value="-1316.7" spread="892.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3+38+DR+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.350</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.9</ci_lower_limit>
            <ci_upper_limit>46.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3+38+DR+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.697</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.3</ci_lower_limit>
            <ci_upper_limit>52.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3+38+DR+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-49.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-135.2</ci_lower_limit>
            <ci_upper_limit>36.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3+38+DR+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-30.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.6</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3-38+DR+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>22.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3-38+DR+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.910</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.4</ci_lower_limit>
            <ci_upper_limit>35.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3-38+DR+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.718</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.1</ci_lower_limit>
            <ci_upper_limit>30.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6+CXCR3-38+DR+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.687</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.4</ci_lower_limit>
            <ci_upper_limit>23.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3+38+DR+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-56.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-249.8</ci_lower_limit>
            <ci_upper_limit>137.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3+38+DR+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.470</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>51.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-93.9</ci_lower_limit>
            <ci_upper_limit>197.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3+38+DR+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-141.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-829.2</ci_lower_limit>
            <ci_upper_limit>546.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3+38+DR+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-137.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-294.0</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3-38+DR+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.989</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.5</ci_lower_limit>
            <ci_upper_limit>61.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3-38+DR+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.634</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-17.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-94.3</ci_lower_limit>
            <ci_upper_limit>59.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3-38+DR+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.789</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>59.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-395.2</ci_lower_limit>
            <ci_upper_limit>513.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+3+8-4+CCR6-CXCR3-38+DR+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-47.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-135.5</ci_lower_limit>
            <ci_upper_limit>41.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3682.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2511.9</ci_lower_limit>
            <ci_upper_limit>9876.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.875</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-547.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7612.6</ci_lower_limit>
            <ci_upper_limit>6517.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.815</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1106.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10706.0</ci_lower_limit>
            <ci_upper_limit>8494.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3631.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9738.9</ci_lower_limit>
            <ci_upper_limit>2476.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.489</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-515.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2021.4</ci_lower_limit>
            <ci_upper_limit>990.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.822</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-199.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2001.7</ci_lower_limit>
            <ci_upper_limit>1602.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.784</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-253.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2136.7</ci_lower_limit>
            <ci_upper_limit>1629.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.804</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>225.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1633.1</ci_lower_limit>
            <ci_upper_limit>2083.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3-, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.719</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>162.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-754.5</ci_lower_limit>
            <ci_upper_limit>1079.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3-, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.742</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-183.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1317.4</ci_lower_limit>
            <ci_upper_limit>950.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3-, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.658</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-268.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1507.5</ci_lower_limit>
            <ci_upper_limit>970.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6+CXCR3-, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.755</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-197.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1499.3</ci_lower_limit>
            <ci_upper_limit>1104.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1150.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1250.0</ci_lower_limit>
            <ci_upper_limit>3550.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.891</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-268.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4269.2</ci_lower_limit>
            <ci_upper_limit>3733.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.633</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1347.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7073.1</ci_lower_limit>
            <ci_upper_limit>4378.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.410</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1688.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5864.1</ci_lower_limit>
            <ci_upper_limit>2486.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3-, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3276.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1786.0</ci_lower_limit>
            <ci_upper_limit>8339.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3-, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.894</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-447.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7285.5</ci_lower_limit>
            <ci_upper_limit>6390.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3-, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.600</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1435.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4101.4</ci_lower_limit>
            <ci_upper_limit>6972.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD45+CD3+CD8-CD4+CCR6-CXCR3-, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.534</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1210.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5213.1</ci_lower_limit>
            <ci_upper_limit>2792.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16-, CD14lo+CD16br+</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16- and CD14lo+CD16br+. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16- and CD14lo+CD16br+ (10^3/Liter) baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16-, CD14lo+CD16br+</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16- and CD14lo+CD16br+. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD14-HLA-DR+CD11cbr+CD123-, CD14br+CD16+, CD14br+CD16- and CD14lo+CD16br+ (10^3/Liter) baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>10^3 cells/Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD14-HLA-DR+CD11cbr+CD123-, Week 1, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2017.6" spread="2452.91"/>
                    <measurement group_id="O2" value="738.7" spread="1266.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14-HLA-DR+CD11cbr+CD123-, Week 4, n=6, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2766.3" spread="3220.54"/>
                    <measurement group_id="O2" value="2278.8" spread="1696.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14-HLA-DR+CD11cbr+CD123-, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5730.4" spread="5085.86"/>
                    <measurement group_id="O2" value="5453.0" spread="2399.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14-HLA-DR+CD11cbr+CD123-, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5785.6" spread="5081.59"/>
                    <measurement group_id="O2" value="5474.0" spread="2439.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16+, Week 1, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5376.0" spread="4748.95"/>
                    <measurement group_id="O2" value="1491.0" spread="2452.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16+, Week 4, n=6, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5635.3" spread="5971.99"/>
                    <measurement group_id="O2" value="2724.3" spread="3117.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16+, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25351.6" spread="9433.73"/>
                    <measurement group_id="O2" value="2668.0" spread="4589.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8557.2" spread="9914.93"/>
                    <measurement group_id="O2" value="4800.0" spread="5266.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16-, Week 1, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40079.7" spread="40456.86"/>
                    <measurement group_id="O2" value="17662.7" spread="21211.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16-, Week 4, n=6, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17173.8" spread="24181.15"/>
                    <measurement group_id="O2" value="10485.9" spread="12635.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16-, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2981.8" spread="37788.70"/>
                    <measurement group_id="O2" value="13201.2" spread="18684.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14br+CD16-, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31906.6" spread="45766.70"/>
                    <measurement group_id="O2" value="-31512.8" spread="24027.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14lo+CD16br+, Week 1, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11248.2" spread="6598.36"/>
                    <measurement group_id="O2" value="4334.6" spread="3466.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14lo+CD16br+, Week 4, n=6, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2522.9" spread="3757.96"/>
                    <measurement group_id="O2" value="291.3" spread="1959.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14lo+CD16br+, Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10938.4" spread="5088.36"/>
                    <measurement group_id="O2" value="759.2" spread="2534.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD14lo+CD16br+, 12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24737.0" spread="7758.65"/>
                    <measurement group_id="O2" value="3992.8" spread="4134.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14-HLA-DR+CD11cbr+CD123-, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.328</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2756.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2953.7</ci_lower_limit>
            <ci_upper_limit>8466.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14-HLA-DR+CD11cbr+CD123-, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.895</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-487.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8003.7</ci_lower_limit>
            <ci_upper_limit>7028.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14-HLA-DR+CD11cbr+CD123-, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.961</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-277.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12001.0</ci_lower_limit>
            <ci_upper_limit>11446.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14-HLA-DR+CD11cbr+CD123-, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.956</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-311.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11960.5</ci_lower_limit>
            <ci_upper_limit>11337.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6866.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4230.7</ci_lower_limit>
            <ci_upper_limit>17964.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8359.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5533.3</ci_lower_limit>
            <ci_upper_limit>22252.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22683.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44298.5</ci_lower_limit>
            <ci_upper_limit>-1068.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.741</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3757.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27146.0</ci_lower_limit>
            <ci_upper_limit>19631.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16-, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.628</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22417.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-116677.8</ci_lower_limit>
            <ci_upper_limit>71843.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16-, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.321</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>27659.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28567.8</ci_lower_limit>
            <ci_upper_limit>83887.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16-, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.704</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>16182.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70377.0</ci_lower_limit>
            <ci_upper_limit>102742.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14br+CD16-, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-63419.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-170364.9</ci_lower_limit>
            <ci_upper_limit>43526.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14lo+CD16br+, Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6913.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22588.4</ci_lower_limit>
            <ci_upper_limit>8761.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14lo+CD16br+, Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2231.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10976.8</ci_lower_limit>
            <ci_upper_limit>6513.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14lo+CD16br+, Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10179.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21827.4</ci_lower_limit>
            <ci_upper_limit>1469.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD14lo+CD16br+, 12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-20744.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38771.8</ci_lower_limit>
            <ci_upper_limit>-2716.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-CD16+CD66b+</title>
        <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD14-CD16+CD66b+ cell. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD14-CD16+CD66b+ (10^6/Liter) baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Cytometry: CD16+ Monocyte Panel: CD14-CD16+CD66b+</title>
          <description>Whole blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Flow cytometry assessment included assessment of CD14-CD16+CD66b+ cell. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for CD14-CD16+CD66b+ (10^6/Liter) baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>10^6 cells/Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, n=5, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-559.0" spread="269.84"/>
                    <measurement group_id="O2" value="-380.9" spread="137.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=6, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-581.9" spread="377.03"/>
                    <measurement group_id="O2" value="-41.5" spread="196.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-125.9" spread="460.53"/>
                    <measurement group_id="O2" value="-378.6" spread="229.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=5, 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-240.9" spread="430.65"/>
                    <measurement group_id="O2" value="-199.3" spread="219.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.564</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>178.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-448.3</ci_lower_limit>
            <ci_upper_limit>804.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.216</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>540.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-335.7</ci_lower_limit>
            <ci_upper_limit>1416.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.629</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-252.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1326.0</ci_lower_limit>
            <ci_upper_limit>820.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.932</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>41.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-962.2</ci_lower_limit>
            <ci_upper_limit>1045.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Biomarkers: Complement Component 3 (C3), Complement Component 4 (C4)</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Complement biomarkers included analysis of Complement C3 and Complement C4. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Biomarkers: Complement Component 3 (C3), Complement Component 4 (C4)</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Complement biomarkers included analysis of Complement C3 and Complement C4. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of complement biomarker</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complement C3, Week 1, n=9, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.967" spread="7.43"/>
                    <measurement group_id="O2" value="0.982" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.957" spread="11.72"/>
                    <measurement group_id="O2" value="0.963" spread="14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" spread="18.42"/>
                    <measurement group_id="O2" value="0.959" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.060" spread="12.00"/>
                    <measurement group_id="O2" value="0.991" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" spread="12.54"/>
                    <measurement group_id="O2" value="1.009" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" spread="9.37"/>
                    <measurement group_id="O2" value="1.003" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C3, 12-Week FU, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" spread="19.15"/>
                    <measurement group_id="O2" value="0.995" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, Week 1, n=9, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" spread="11.40"/>
                    <measurement group_id="O2" value="0.969" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.949" spread="9.64"/>
                    <measurement group_id="O2" value="0.984" spread="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.999" spread="12.06"/>
                    <measurement group_id="O2" value="0.945" spread="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.990" spread="10.31"/>
                    <measurement group_id="O2" value="0.985" spread="17.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" spread="7.66"/>
                    <measurement group_id="O2" value="1.006" spread="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.942" spread="15.57"/>
                    <measurement group_id="O2" value="0.994" spread="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4, 12-Week FU, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.982" spread="12.88"/>
                    <measurement group_id="O2" value="0.986" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Complement Biomarkers: Complement Component 4a (C4a), Complement Component 5a (C5a), Complement Split Factor SC5b-9, Soluble Cluster of Differentiation 163 (sCD163)</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Complement biomarkers included analysis of Complement C4a, Complement C5a, Complement Split Factor SC5b-9 and Soluble CD163. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Complement Biomarkers: Complement Component 4a (C4a), Complement Component 5a (C5a), Complement Split Factor SC5b-9, Soluble Cluster of Differentiation 163 (sCD163)</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Complement biomarkers included analysis of Complement C4a, Complement C5a, Complement Split Factor SC5b-9 and Soluble CD163. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of complement biomarker</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complement C4a, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.159" spread="115.81"/>
                    <measurement group_id="O2" value="0.990" spread="67.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4a, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.881" spread="55.58"/>
                    <measurement group_id="O2" value="1.156" spread="75.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4a, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.840" spread="40.85"/>
                    <measurement group_id="O2" value="1.100" spread="46.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4a, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.914" spread="66.71"/>
                    <measurement group_id="O2" value="0.860" spread="53.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4a, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="44.16"/>
                    <measurement group_id="O2" value="0.998" spread="60.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4a, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" spread="58.05"/>
                    <measurement group_id="O2" value="0.901" spread="93.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C4a, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.104" spread="40.27"/>
                    <measurement group_id="O2" value="1.221" spread="56.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" spread="19.42"/>
                    <measurement group_id="O2" value="0.991" spread="29.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.154" spread="36.82"/>
                    <measurement group_id="O2" value="1.015" spread="55.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.943" spread="16.76"/>
                    <measurement group_id="O2" value="1.010" spread="35.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.139" spread="61.77"/>
                    <measurement group_id="O2" value="1.044" spread="33.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" spread="13.71"/>
                    <measurement group_id="O2" value="0.957" spread="26.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.012" spread="8.41"/>
                    <measurement group_id="O2" value="0.995" spread="29.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement C5a, 12-Week FU, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.152" spread="42.75"/>
                    <measurement group_id="O2" value="1.130" spread="32.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.971" spread="37.46"/>
                    <measurement group_id="O2" value="1.020" spread="43.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.078" spread="28.80"/>
                    <measurement group_id="O2" value="1.040" spread="60.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.930" spread="43.01"/>
                    <measurement group_id="O2" value="1.126" spread="41.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" spread="23.18"/>
                    <measurement group_id="O2" value="1.084" spread="53.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889" spread="35.48"/>
                    <measurement group_id="O2" value="1.055" spread="67.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.883" spread="30.26"/>
                    <measurement group_id="O2" value="0.843" spread="72.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complement Split Factor SC5b-9,12-Week FU, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" spread="69.05"/>
                    <measurement group_id="O2" value="1.041" spread="38.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.993" spread="24.28"/>
                    <measurement group_id="O2" value="0.963" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.101" spread="17.80"/>
                    <measurement group_id="O2" value="0.954" spread="17.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.986" spread="15.89"/>
                    <measurement group_id="O2" value="0.947" spread="27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.938" spread="20.83"/>
                    <measurement group_id="O2" value="0.959" spread="30.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.938" spread="30.03"/>
                    <measurement group_id="O2" value="0.950" spread="28.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" spread="24.86"/>
                    <measurement group_id="O2" value="0.915" spread="35.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sCD163, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.200" spread="32.94"/>
                    <measurement group_id="O2" value="0.994" spread="28.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mechanistic Biomarkers</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Mechanistic biomarkers included analysis of Interleukin 1 Beta, Interleukin 10, Interleukin 15, Interleukin 17 Alpha, Interleukin 17F, Interleukin 8 and Tumor Necrosis Factor. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. NA indicates that data is not available since 100% of the data was below limit of quantification at all time points. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6, 8, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mechanistic Biomarkers</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Mechanistic biomarkers included analysis of Interleukin 1 Beta, Interleukin 10, Interleukin 15, Interleukin 17 Alpha, Interleukin 17F, Interleukin 8 and Tumor Necrosis Factor. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. NA indicates that data is not available since 100% of the data was below limit of quantification at all time points. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of mechanistic biomarker</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin 1 Beta, Week 1, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1 Beta, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1 Beta, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1 Beta, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1 Beta, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1 Beta, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1 Beta, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                    <measurement group_id="O2" value="1.000" spread="NA">100% of data was below limit of quantification at all time points, hence no variability.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, Week 1, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.962" spread="11.55"/>
                    <measurement group_id="O2" value="0.994" spread="28.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.206" spread="45.35"/>
                    <measurement group_id="O2" value="1.048" spread="37.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" spread="41.69"/>
                    <measurement group_id="O2" value="0.985" spread="32.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842" spread="47.84"/>
                    <measurement group_id="O2" value="0.960" spread="17.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.197" spread="50.41"/>
                    <measurement group_id="O2" value="0.969" spread="30.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842" spread="47.84"/>
                    <measurement group_id="O2" value="0.989" spread="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 10, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842" spread="47.84"/>
                    <measurement group_id="O2" value="1.230" spread="62.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, Week 1, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.001" spread="12.70"/>
                    <measurement group_id="O2" value="0.950" spread="59.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.882" spread="41.99"/>
                    <measurement group_id="O2" value="0.849" spread="102.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.206" spread="47.87"/>
                    <measurement group_id="O2" value="0.831" spread="84.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.297" spread="48.81"/>
                    <measurement group_id="O2" value="0.904" spread="90.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="37.95"/>
                    <measurement group_id="O2" value="0.865" spread="90.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="37.95"/>
                    <measurement group_id="O2" value="0.771" spread="82.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 15, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" spread="37.95"/>
                    <measurement group_id="O2" value="0.636" spread="111.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, Week 1, n=9, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.806" spread="53.03"/>
                    <measurement group_id="O2" value="1.054" spread="93.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, Week 2, n=8, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.935" spread="75.58"/>
                    <measurement group_id="O2" value="0.942" spread="72.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, Week 4, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.995" spread="91.45"/>
                    <measurement group_id="O2" value="0.911" spread="102.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, Week 6, n=7, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.015" spread="76.60"/>
                    <measurement group_id="O2" value="0.867" spread="90.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, Week 8, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" spread="77.24"/>
                    <measurement group_id="O2" value="1.005" spread="135.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, Week 12, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" spread="87.84"/>
                    <measurement group_id="O2" value="0.857" spread="101.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17 Alpha, 12-Week FU, n=7, 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" spread="155.67"/>
                    <measurement group_id="O2" value="0.999" spread="150.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, Week 1, n=9, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.153" spread="36.21"/>
                    <measurement group_id="O2" value="0.797" spread="78.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.062" spread="74.38"/>
                    <measurement group_id="O2" value="0.911" spread="72.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, Week 4, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966" spread="21.09"/>
                    <measurement group_id="O2" value="0.948" spread="89.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, Week 6, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.787" spread="32.55"/>
                    <measurement group_id="O2" value="1.013" spread="107.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.947" spread="19.20"/>
                    <measurement group_id="O2" value="0.815" spread="91.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, Week 12, n=7, 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" spread="74.09"/>
                    <measurement group_id="O2" value="0.884" spread="100.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 17F, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.130" spread="101.51"/>
                    <measurement group_id="O2" value="0.741" spread="90.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, Week 1, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.104" spread="40.98"/>
                    <measurement group_id="O2" value="1.081" spread="74.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.505" spread="43.78"/>
                    <measurement group_id="O2" value="0.861" spread="78.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.102" spread="38.30"/>
                    <measurement group_id="O2" value="0.773" spread="82.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.229" spread="61.82"/>
                    <measurement group_id="O2" value="0.720" spread="72.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.547" spread="53.88"/>
                    <measurement group_id="O2" value="0.761" spread="80.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.240" spread="49.03"/>
                    <measurement group_id="O2" value="0.850" spread="80.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.191" spread="42.58"/>
                    <measurement group_id="O2" value="0.841" spread="96.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, Week 1, n=9, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" spread="15.20"/>
                    <measurement group_id="O2" value="0.994" spread="18.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, Week 2, n=8, 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.951" spread="19.84"/>
                    <measurement group_id="O2" value="0.977" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, Week 4, n=9, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.933" spread="17.70"/>
                    <measurement group_id="O2" value="0.871" spread="48.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, Week 6, n=7, 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.087" spread="36.81"/>
                    <measurement group_id="O2" value="0.929" spread="21.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, Week 8, n=7, 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.110" spread="25.33"/>
                    <measurement group_id="O2" value="0.930" spread="20.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" spread="38.53"/>
                    <measurement group_id="O2" value="0.969" spread="29.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor,12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.619" spread="180.16"/>
                    <measurement group_id="O2" value="1.057" spread="34.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Safety Biomarkers: 3B-Cholestenoic Acid, Surfactant Protein D</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Safety biomarkers included analysis of 3B-Cholestenoic Acid and Surfactant Protein D. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Week 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Safety Biomarkers: 3B-Cholestenoic Acid, Surfactant Protein D</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Safety biomarkers included analysis of 3B-Cholestenoic Acid and Surfactant Protein D. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of safety biomarker</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3B-Cholestenoic Acid, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.012" spread="16.52"/>
                    <measurement group_id="O2" value="1.094" spread="19.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3B-Cholestenoic Acid, Week 22, n=7, 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.020" spread="20.25"/>
                    <measurement group_id="O2" value="1.009" spread="22.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surfactant Protein D, Week 12, n=7, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.003" spread="23.10"/>
                    <measurement group_id="O2" value="1.134" spread="27.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surfactant Protein D, 12-Week FU, n=7, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.140" spread="45.71"/>
                    <measurement group_id="O2" value="0.985" spread="31.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Safety Biomarkers: KL-6 Antigen</title>
        <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Safety biomarker included analysis of KL-6 Antigen. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Week 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Safety Biomarkers: KL-6 Antigen</title>
          <description>Blood samples were collected and analyzed for markers which may be predictive of rheumatoid arthritis disease activity. Safety biomarker included analysis of KL-6 Antigen. Baseline was defined at Day 1. Change from Baseline was calculated as ratio of Baseline value to post-dose value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Ratio of safety biomarker</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12, n=6, 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.416" spread="220.58"/>
                    <measurement group_id="O2" value="1.099" spread="66.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=6, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" spread="62.43"/>
                    <measurement group_id="O2" value="1.024" spread="93.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)</title>
        <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. An AESI include serious infections, opportunistic infections, neutropenia, respiratory events, pulmonary alveolar proteinosis, hypersensitivity reactions, injection site reactions, persistent cough or dyspnea.</description>
        <time_frame>Up to 12-Week FU (Week 22)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)</title>
          <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. An AESI include serious infections, opportunistic infections, neutropenia, respiratory events, pulmonary alveolar proteinosis, hypersensitivity reactions, injection site reactions, persistent cough or dyspnea.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Tested Positive for Anti-GSK3196165 Binding Antibody Detection at Any Time Post-Baseline</title>
        <description>Immunogenicity samples for determination of anti-drug-antibody (ADA) were collected. The presence of treatment emergent ADA was determined using a GSK3196165 bridging style ADA assay with a bio-analytically determined cut point determined during assay validation. Samples taken after dosing with GSK3196165 that had a value at or above the cut-point was considered potentially treatment-emergent ADA-positive. The immunogenicity population consisted of all participants in the ITT population, who had at least one valid immunogenicity assessment.</description>
        <time_frame>Up to 12-Week FU (Week 22)</time_frame>
        <population>Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Tested Positive for Anti-GSK3196165 Binding Antibody Detection at Any Time Post-Baseline</title>
          <description>Immunogenicity samples for determination of anti-drug-antibody (ADA) were collected. The presence of treatment emergent ADA was determined using a GSK3196165 bridging style ADA assay with a bio-analytically determined cut point determined during assay validation. Samples taken after dosing with GSK3196165 that had a value at or above the cut-point was considered potentially treatment-emergent ADA-positive. The immunogenicity population consisted of all participants in the ITT population, who had at least one valid immunogenicity assessment.</description>
          <population>Immunogenicity Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Synovitis as Assessed by Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) in the Most Affected Hand/Wrist</title>
        <description>For synovitis a total of 8 joints were evaluated. Individual joint scores range from 0-3, where 0= normal, 1=mild, 2=moderate and 3=severe. The final synovitis score is the sum of the individual joint scores. Total score range from 0 (best) to 24 (worst). If an individual location is scored either 'Not Visible' or 'Surgically Modified' then the score for that location was set to missing. Missing joint scores was imputed as the mean of the non-missing joint scores. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Repeated measures analysis adjusted for synovitis score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Data has been presented for Median and 95% credible interval. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Synovitis as Assessed by Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) in the Most Affected Hand/Wrist</title>
          <description>For synovitis a total of 8 joints were evaluated. Individual joint scores range from 0-3, where 0= normal, 1=mild, 2=moderate and 3=severe. The final synovitis score is the sum of the individual joint scores. Total score range from 0 (best) to 24 (worst). If an individual location is scored either 'Not Visible' or 'Surgically Modified' then the score for that location was set to missing. Missing joint scores was imputed as the mean of the non-missing joint scores. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Repeated measures analysis adjusted for synovitis score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Data has been presented for Median and 95% credible interval. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=6, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-1.92" upper_limit="1.95"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-1.19" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="-1.57" upper_limit="3.12"/>
                    <measurement group_id="O2" value="-1.33" lower_limit="-2.54" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=7, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="-1.32" upper_limit="3.55"/>
                    <measurement group_id="O2" value="-1.13" lower_limit="-2.47" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4, For Posterior Probability Difference &lt;0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.547</p_value>
            <method>Repeated Measures Bayesian Model</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12, For Posterior Probability Difference &lt;0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Repeated Measures Bayesian Model</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.77</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU, For Posterior Probability Difference &lt;0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>Repeated Measures Bayesian Model</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.02</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4, For Posterior Probability Difference &gt;0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.453</p_value>
            <method>Repeated Measures Bayesian Model</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12, For Posterior Probability Difference &gt;0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Repeated Measures Bayesian Model</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.77</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU, For Posterior Probability Difference &gt;0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.051</p_value>
            <method>Repeated Measures Bayesian Model</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.02</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Osteitis as Assessed by OMERACT RAMRI Scoring System in the Most Affected Hand/Wrist</title>
        <description>For bone edema/osteitis a total of 25 locations was evaluated. Individual location scores ranged from 0-3, where, 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100% of bone edematous. Final bone edema/osteitis score is sum of individual location scores. Total score ranged from 0 (best) to 75 (worst). Baseline was defined at Day 1. Change from Baseline was calculated by subtracting post-dose value from Baseline value. If an individual location was scored either 'Not Visible' or 'Surgically Modified' or 'Not Assessable' then the score for that location was set to be missing. Missing joint scores was imputed as mean of non-missing location scores. Repeated measures analysis adjusted for Bone Edema/Osteitis Score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Osteitis as Assessed by OMERACT RAMRI Scoring System in the Most Affected Hand/Wrist</title>
          <description>For bone edema/osteitis a total of 25 locations was evaluated. Individual location scores ranged from 0-3, where, 0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100% of bone edematous. Final bone edema/osteitis score is sum of individual location scores. Total score ranged from 0 (best) to 75 (worst). Baseline was defined at Day 1. Change from Baseline was calculated by subtracting post-dose value from Baseline value. If an individual location was scored either 'Not Visible' or 'Surgically Modified' or 'Not Assessable' then the score for that location was set to be missing. Missing joint scores was imputed as mean of non-missing location scores. Repeated measures analysis adjusted for Bone Edema/Osteitis Score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=6, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.11"/>
                    <measurement group_id="O2" value="-0.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.04"/>
                    <measurement group_id="O2" value="-0.8" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=7,19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.33"/>
                    <measurement group_id="O2" value="-0.9" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.940</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.521</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.396</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erosion as Assessed by OMERACT RAMRI Scoring System in the Most Affected Hand/Wrist</title>
        <description>For bone erosion a total of 25 locations were evaluated. Individual location scores range from 0-10, where, 0: no erosion; 1: 1-10% of bone eroded and 10: 91-100% of bone eroded. The final bone erosion score is the sum of the individual location scores. The total score ranged from 0 (best) to 250 (worst). If an individual location was scored either 'Not Visible' or 'Surgically Modified' or 'Not Assessable' then the score for that location was set to be missing. Missing joint scores was imputed as the mean of the non-missing location scores. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for Bone Erosion Score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles.</description>
        <time_frame>Baseline and Weeks 4, 12, 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erosion as Assessed by OMERACT RAMRI Scoring System in the Most Affected Hand/Wrist</title>
          <description>For bone erosion a total of 25 locations were evaluated. Individual location scores range from 0-10, where, 0: no erosion; 1: 1-10% of bone eroded and 10: 91-100% of bone eroded. The final bone erosion score is the sum of the individual location scores. The total score ranged from 0 (best) to 250 (worst). If an individual location was scored either 'Not Visible' or 'Surgically Modified' or 'Not Assessable' then the score for that location was set to be missing. Missing joint scores was imputed as the mean of the non-missing location scores. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Analysis was performed using repeated measures analysis adjusted for Bone Erosion Score baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles.</description>
          <population>ITT Population.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=6, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.49"/>
                    <measurement group_id="O2" value="0.3" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.50"/>
                    <measurement group_id="O2" value="0.4" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=7, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.47"/>
                    <measurement group_id="O2" value="0.5" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.475</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Synovitis as Assessed by Rheumatoid Arthritis MRI Quantitative (RAMRIQ) Assessment in the Most Affected Hand/Wrist</title>
        <description>RAMRIQ is an automated volume quantification assessment. RAMRIQ assessed same pathologies and joints (except metacarpophalangeal joint [MCP1]) as RAMRIS allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using active appearance modelling (AAMs). Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D regions of interest (ROI) for synovial enhancement across all time points. Synovial volume was calculated as voxels that enhance within each ROI. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Repeated measures analysis adjusted for Synovitis baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 12 and 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Synovitis as Assessed by Rheumatoid Arthritis MRI Quantitative (RAMRIQ) Assessment in the Most Affected Hand/Wrist</title>
          <description>RAMRIQ is an automated volume quantification assessment. RAMRIQ assessed same pathologies and joints (except metacarpophalangeal joint [MCP1]) as RAMRIS allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using active appearance modelling (AAMs). Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D regions of interest (ROI) for synovial enhancement across all time points. Synovial volume was calculated as voxels that enhance within each ROI. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Repeated measures analysis adjusted for Synovitis baseline value, treatment group, disease duration (&lt;=2 or &gt;2 years), visit and treatment group by visit interaction. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=6, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="1052.52"/>
                    <measurement group_id="O2" value="245.5" spread="776.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-912.3" spread="1405.77"/>
                    <measurement group_id="O2" value="-1417.0" spread="671.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=7, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364.0" spread="1372.20"/>
                    <measurement group_id="O2" value="-1172.1" spread="844.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.874</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>211.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2589.2</ci_lower_limit>
            <ci_upper_limit>3012.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.749</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-504.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3730.4</ci_lower_limit>
            <ci_upper_limit>2720.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1536.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4884.2</ci_lower_limit>
            <ci_upper_limit>1812.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Osteitis as Assessed by RAMRIQ Assessment in the Most Affected Hand/Wrist</title>
        <description>RAMRIQ is an automated volume quantification assessment for edema volume. RAMRIQ assessed the same pathologies and joints (except MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs. Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D ROI for synovial enhancement across all time points. Edema volume was defined as non-erosion contrast-enhancing voxels inside the bone. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 12 and 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Osteitis as Assessed by RAMRIQ Assessment in the Most Affected Hand/Wrist</title>
          <description>RAMRIQ is an automated volume quantification assessment for edema volume. RAMRIQ assessed the same pathologies and joints (except MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs. Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D ROI for synovial enhancement across all time points. Edema volume was defined as non-erosion contrast-enhancing voxels inside the bone. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=6, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0045" spread="0.0102"/>
                    <measurement group_id="O2" value="0.0084" spread="0.0057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0045" spread="0.0035"/>
                    <measurement group_id="O2" value="-0.0009" spread="0.0019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=7, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0038" spread="0.0016"/>
                    <measurement group_id="O2" value="-0.0027" spread="0.0009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0128</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0123</ci_lower_limit>
            <ci_upper_limit>0.0380</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.375</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0036</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0046</ci_lower_limit>
            <ci_upper_limit>0.0118</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0028</ci_lower_limit>
            <ci_upper_limit>0.0049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erosion as Assessed by RAMRIQ Assessment in the Most Affected Hand/Wrist</title>
        <description>RAMRIQ is an automated volume quantification assessment for erosion volume. RAMRIQ assessed the same pathologies and joints (except MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs. Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D ROI for synovial enhancement across all time points. Erosion volume was identified inside the bone surfaces using voxel-based classification. The volume of BME and erosions was normalised to total bone volume for statistical analysis. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 12 and 12-Week FU (Week 22)</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK3196165 180 mg</title>
            <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erosion as Assessed by RAMRIQ Assessment in the Most Affected Hand/Wrist</title>
          <description>RAMRIQ is an automated volume quantification assessment for erosion volume. RAMRIQ assessed the same pathologies and joints (except MCP1) as RAMRIS, allowing for direct comparison of results obtained using the two methods. Bones were automatically identified in pre-contrast, coronal T1 images using AAMs. Joint capsules and soft tissues were also segmented with AAMs, providing consistent 3D ROI for synovial enhancement across all time points. Erosion volume was identified inside the bone surfaces using voxel-based classification. The volume of BME and erosions was normalised to total bone volume for statistical analysis. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</description>
          <population>ITT Population.</population>
          <units>Milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=6, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0007" spread="0.0012"/>
                    <measurement group_id="O2" value="0.0006" spread="0.0008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=5, 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0003" spread="0.0011"/>
                    <measurement group_id="O2" value="-0.0000" spread="0.0006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Week FU, n=7, 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0002" spread="0.0023"/>
                    <measurement group_id="O2" value="0.0003" spread="0.0013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.0002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0033</ci_lower_limit>
            <ci_upper_limit>0.0029</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.0004</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0028</ci_lower_limit>
            <ci_upper_limit>0.0021</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12-Week FU</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.850</p_value>
            <method>Repeated measures analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0048</ci_lower_limit>
            <ci_upper_limit>0.0058</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected from start of study treatment up to 12-Week FU (Week 22).</time_frame>
      <desc>ITT Population was used for the analysis of safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Eligible participants received matching placebo SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to placebo, participants also received MTX 7.5–25 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
        </group>
        <group group_id="E2">
          <title>GSK3196165 180 mg</title>
          <description>Eligible participants received GSK3196165 180 mg SC into thigh or abdomen once weekly for 5 weeks, and then every other week until Week 10. In addition to GSK3196165, participants also received MTX 7.5–5 mg/week and folic (or folinic) acid &gt;=5 mg/week during the combination treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

